期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 19, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/ijms19082448
关键词
extracellular vesicles; multiple sclerosis; fingolimod; miRNA; immune regulation; exosomes
资金
- Rio Hortega program of the Instituto de Salud Carlos III [CM14/00006]
- Basque Government [PRE_2015_0341, PRE_2014_1_7]
- Spanish Association Against Cancer (AECC)
- Novartis
Extracellular vesicles (EVs) are membrane-bound particles involved in intercellular communication. They carry proteins, lipids, and nucleotides such as microRNAs (miRNAs) from the secreting cell that can modulate target cells. We and others have previously described the presence of EVs in peripheral blood of multiple sclerosis (MS) patients and postulated them as novel biomarkers. However, their immune function in MS pathogenesis and the effect during the onset of new immunomodulatory therapies on EVs remain elusive. Here, we isolated plasma EVs from fingolimod-treated MS patients in order to assess whether EVs are affected by the first dose of the treatment. We quantified EVs, analyzed their miRNA cargo, and checked their immune regulatory function. Results showed an elevated EV concentration with a dramatic change in their miRNA cargo 5 h after the first dose of fingolimod. Besides, EVs obtained prior to fingolimod treatment showed an increased immune regulatory activity compared to EVs obtained 5 h post-treatment. This work suggests that EVs are implicated in the mechanism of action of immunomodulatory treatments from the initial hours and opens a new avenue to explore a potential use of EVs for early treatment monitoring.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据